Clinical Trial Update: A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single and repeat IV doses of GSK2251052 in healthy volunteers; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Infection
• Infection

Drugs mentioned

• GSK2251052 (GSK2251052)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Community-acquired Infection | Phase 1 | Status: TERMINATED